尿激酶型纤溶酶原激活剂细胞受体的蛋白质结构与膜锚定 - Suppr

Suppr

超能文献

Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.

作者信息

Ploug M, Behrendt N, Løber D, Danø K

机构信息

Finsen Laboratory, Copenhagen O, Denmark.

出版信息

Semin Thromb Hemost. 1991 Jul;17(3):183-93. doi: 10.1055/s-2007-1002608.

DOI:10.1055/s-2007-1002608

PMID:1665583

Abstract

摘要

相似文献

Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.尿激酶型纤溶酶原激活剂细胞受体的蛋白质结构与膜锚定

Semin Thromb Hemost. 1991 Jul;17(3):183-93. doi: 10.1055/s-2007-1002608.

The urokinase-type plasminogen activator receptor is a member of the Ly-6 superfamily.尿激酶型纤溶酶原激活物受体是Ly-6超家族的成员之一。

Immunol Today. 1991 May;12(5):170. doi: 10.1016/S0167-5699(05)80051-9.

[Structure and characteristics of singer chain urokinase-type plasminogen activator].

Sheng Li Ke Xue Jin Zhan. 1990 Oct;21(4):314-7.

[The structure and function of urokinase receptor and its expression in neoplastic tissues].

Zhonghua Yi Xue Za Zhi. 1995 May;75(5):315-7.

Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.尿激酶型纤溶酶原激活剂与其受体相互作用的结构分析：抗侵袭性癌症治疗的潜在靶点。

Biochem Soc Trans. 2002 Apr;30(2):177-83.

Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.通过对尿激酶型纤溶酶原激活剂受体进行光亲和标记来鉴定参与配体结合的特定位点。位于uPAR结构域I和III中同等位置的残基参与复合配体结合位点的组装。

Biochemistry. 1998 Nov 24;37(47):16494-505. doi: 10.1021/bi981203r.

The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.尿激酶受体的结构与功能，一种调控细胞表面纤溶酶原激活的膜蛋白。

Biol Chem Hoppe Seyler. 1995 May;376(5):269-79.

Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).可溶性尿激酶受体（suPAR）与尿激酶氨基末端片段（1-143）复合物的结晶。

Acta Crystallogr D Biol Crystallogr. 2005 Jun;61(Pt 6):697-700. doi: 10.1107/S0907444905014174. Epub 2005 May 26.

Plasminogen activator system in osteoclasts.

J Bone Miner Res. 1997 May;12(5):761-8. doi: 10.1359/jbmr.1997.12.5.761.

Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator.尿激酶型纤溶酶原激活剂氨基末端片段的蛋白质表达及初步晶体学分析

Protein Expr Purif. 2006 Sep;49(1):71-7. doi: 10.1016/j.pep.2006.05.005. Epub 2006 May 20.

引用本文的文献

Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors.细胞外基质改变作为脑肿瘤致痫性的替代危险因素

Biomedicines. 2022 Oct 3;10(10):2475. doi: 10.3390/biomedicines10102475.

Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma.可溶性尿激酶型纤溶酶原激活物受体（suPAR）与成人哮喘疾病转归的关系

J Asthma Allergy. 2022 May 10;15:579-593. doi: 10.2147/JAA.S356083. eCollection 2022.

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.用于肿瘤正电子发射断层扫描和内放射治疗的放射性标记肽

Pharmaceuticals (Basel). 2020 Jan 30;13(2):22. doi: 10.3390/ph13020022.

The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.尿激酶受体在神经球中诱导胶质母细胞瘤细胞的间充质基因表达特征，并促进肿瘤细胞存活。

Sci Rep. 2018 Feb 14;8(1):2982. doi: 10.1038/s41598-018-21358-1.

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.前列腺癌中尿激酶型纤溶酶原激活剂受体（uPAR）的正电子发射断层扫描（PET）成像：现状与未来展望

Clin Transl Imaging. 2016;4(6):457-465. doi: 10.1007/s40336-016-0197-4. Epub 2016 Jul 4.

Urokinase receptor and resistance to targeted anticancer agents.尿激酶受体与对靶向抗癌药物的耐药性

Front Pharmacol. 2015 Jul 27;6:154. doi: 10.3389/fphar.2015.00154. eCollection 2015.

Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.全基因组蛋白质 QTL 图谱分析确定人类血浆激肽释放酶为血清 uPAR 水平的翻译后调控因子。

FASEB J. 2014 Feb;28(2):923-34. doi: 10.1096/fj.13-240879. Epub 2013 Nov 18.

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.尿激酶型纤溶酶原激活物受体（uPAR）作为一种有前景的新型成像靶点：潜在的临床应用

Clin Physiol Funct Imaging. 2013 Sep;33(5):329-37. doi: 10.1111/cpf.12037. Epub 2013 Apr 3.

Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.完整形式和裂解形式的尿激酶受体增强了对出现与结直肠癌相关症状的患者中癌症与非恶性疾病的鉴别。

Br J Cancer. 2009 Sep 15;101(6):992-7. doi: 10.1038/sj.bjc.6605228. Epub 2009 Aug 11.

EGF increases expression and activity of PAs in preimplantation rat embryos and their implantation rate.表皮生长因子可增加大鼠植入前胚胎中纤溶酶原激活剂的表达和活性及其着床率。

Reprod Biol Endocrinol. 2007 Jan 29;5:4. doi: 10.1186/1477-7827-5-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验